Vaxxinity (Vaxxinity) Risk Assessment

View and export this data going back to 2021. Start your Free Trial

What is Vaxxinity Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Vaxxinity is: No Data: Cannot be evaluated.

Competitive Comparison of Vaxxinity's Risk Assessment

For the Biotechnology subindustry, Vaxxinity's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaxxinity's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxxinity's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Vaxxinity's Risk Assessment falls into.

Vaxxinity (OTCPK:VAXX) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Vaxxinity Risk Assessment Related Terms

Thank you for viewing the detailed overview of Vaxxinity's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxxinity (Vaxxinity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxxinity Inc (OTCPK:VAXX) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

505 Odyssey Way, Merritt Island, FL, USA, 32953

Website

https://www.vaxxinity.com

Vaxxinity Inc is engaged in the development and commercialization of prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its pipeline primarily consists of five programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications.

Executives

Sumita Ray	officer: Chief Legal Officer, Secretary	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Prime Movers Lab Fund I Lp	10 percent owner	P.O. BOX 12829, JACKSON WY 83002
Landon E Ogilvie	director	505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Katherine A. Eade	director	C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
James Alan Smith	director	505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Gabrielle B Toledano	director	209 REDWOOD SHORES PARKWAY, REDWOOD CITY CA 94065
Lou Reese	director, officer: Executive Chairman	C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Mei Mei Hu	director, 10 percent owner, officer: See Remarks	C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
United Biomedical Inc	10 percent owner	25 DAVIDS DR, HAUPPAUGE NY 11788
Dakin Sloss	10 percent owner	126 E 56TH ST, 30TH FLOOR, NEW YORK NY 10022
Peter Powchik	director	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Jason Pesile	officer: See Remarks	C/O VAXXINITY, INC., 1717 MAIN ST. STE.3388, DALLAS TX 75201
George R Hornig	director	625 MADISON AVE SUITE 10-B, NEW YORK NY 10017
James Chui	director	C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Peter Diamandis	director	4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292